Chris Gemmiti, Ph.D.SVP of Operations at Sentien Biotechnologies Inc.
Dr. Gemmiti has dedicated his 20+ year career to cell therapy and regenerative medicine, through both industry and academic roles. He is currently the Senior VP of Operations at Sentien, where he has broad operational responsibilities for this clinical-stage MSC company. This includes a key role in opening and executing Sentien’s IND for COVID-19 patients experiencing multi-organ failure. Chris joined Sentien from Harvard’s Wyss Institute, where he guided translation strategy and technical development of early-stage regenerative medicine technologies. Previously, at Organogenesis Inc., he was the business unit Director responsible for the clinical development, FDA approval (2012), and commercial launch of GINTUIT™, the first manufactured allogeneic cell therapy approved by BLA. He holds a PhD in Biomedical Engineering from Georgia Tech, where he was an NSF Fellow in Entrepreneurship, and a BS in BME from Johns Hopkins University. Dr. Gemmiti has served on Advisory Boards at Georgia Tech, Johns Hopkins, Duke University, TERMIS, Cell Therapy Bioprocessing and Alliance for Regenerative Medicine.